Healthcare Industry News: drug-eluting balloon
News Release - January 30, 2009
Cook Medical unveils the Advance Drug-Eluting Balloon and Other Cutting-Edge Devices to Advance Leg Therapy at the ISET 2009 International Symposium on Endovascular TherapyEvent was punctuated by several product introductions and a live case demonstration of percutaneous transluminal angioplasty using a drug-eluting balloon
BLOOMINGTON, Ind., Jan 30, 2009 - (HSMN NewsFeed) - In a live case transmitted from The Heart Center Leipzig/Park Hospital in Leipzig, Germany, a new drug-eluting balloon was used as part of a clinical trial during one of the live case demonstrations at last week’s ISET 2009 International Symposium on Endovascular Therapy. Advance PTX is designed to increase long-term patency in patients with peripheral arterial disease (PAD) and is one of the first PTA balloon catheters to be coated with paclitaxel, an antiproliferative drug that has been used successfully to reduce the risk of arterial restenosis following angioplasty in coronary disease patients.
“Bringing together converging technologies—like devices with pharmaceuticals in the case of the Advance PTX balloon—is a critical step in developing advanced medical devices to improve outcomes in specific patient populations,” said Rob Lyles, vice president and global leader of Cook Medical's peripheral intervention division.
Cook also introduced several products from its premier line of diagnostic and peripheral interventional devices at ISET 2009, including its Approach™ CTO microwires. The Approach CTO microwires are the first .014-inch wires designed specifically for crossing chronic total occlusions and extremely tight lesions in the peripheral arteries, including the SFA, popliteal and tibial arteries.
“The Approach microwire line has several product features that address the challenging anatomy of the leg, an important step in the development of PAD medical technology,” said Lyles. “This latest advancement illustrates Cook’s commitment to exploring every possible technology to treat PAD. At Cook, we continuously strive to improve the quality of our products and, in turn, improve the quality of patient outcomes.”
The microwires are the latest peripheral diagnostic products to support the complete Leg Therapy initiative from Cook, a comprehensive line of advanced minimally invasive access products and interventional devices that addresses the anatomical challenges of treating peripheral arterial disease in the legs. With the launch of the full Leg Therapy Program, Cook will deliver clinically effective interventional solutions to patients who need them most.
Now in its 21st year, the leader in interventional education continues to meet the needs of physicians who recognize the challenges that lie ahead and actively seek the knowledge to meet those challenges. ISET provides the tools – in the form of unbiased, professional education – to lead practitioners into the future of an ever-evolving field. For more information, visit www.iset.org.
About Cook Medical:
Cook Medical was one of the first companies to help popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical procedures. Today, the company integrates minimally invasive medical device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Founded in 1963 and operated as a family-held private corporation, Cook is a past winner of the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. For more information, visit www.cookmedical.com
Source: Cook Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.